Cannabis approvals up year on year according to report

FreshLeaf Analytics, a Southern Cannabis Holdings (SCH) division, has released Australia’s most comprehensive medicinal cannabis Patient, Product and Pricing Analysis.

The study was conducted in Q3 2019 and includes insights into the pricing and availability of legal medicinal cannabis products in the Australian marketplace including:

• Number of products in market jumps 40% in 6 months

• Patient growth continues at break-neck speed, up 1000% year on year

• Overall spend declines as doctors go for cheaper products

• Issues around vehicle driving and government subsidies remain

The report has been welcomed by the sector, with key players commenting:

Dr Sanjay Nijhawan, Medical Director of Cannabis Access Clinics: “It is encouraging to see that more patients are getting access to medicine that may help their condition”.

Tim Drury, CEO of Southern Cannabis Holdings: “The market has hit a tipping point here in Australia, and other pharmaceutical-style cannabis markets are looking to Australia as a source of best-practice in product standards, patient monitoring, clinical services and research”.

The report was developed using patient data that was analysed over a period of July – August 2019. A full copy of the report can be downloaded.

You may also like Southport medicinal cannabis manufacturing facility opens